menu
    • menu
    [{"orgOrder":0,"company":"HengRui","sponsor":"Hutchmed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Miscellaneous","year":"2024","type":"Collaboration","leadProduct":"Surufatinib","moa":"||Fibroblast growth factor receptor 1 | Vascular endothelial growth factor receptor","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"HengRui","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HengRui \/ HengRui","highestDevelopmentStatusID":"9","companyTruncated":"HengRui \/ HengRui"},{"orgOrder":0,"company":"HengRui","sponsor":"Hutchmed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Fruquintinib","moa":"||Vascular endothelial growth factor receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"HengRui","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"HengRui \/ HengRui","highestDevelopmentStatusID":"15","companyTruncated":"HengRui \/ HengRui"}]

    Find Clinical Drug Pipeline Developments & Deals by HengRui

    Menu

    HengRui

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            HengRui

                            U.S.A arrow
                            Luxepack
                            Not Confirmed

                            HengRui

                            U.S.A arrow
                            Luxepack
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Surufatinib,Camrelizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase II/ Phase III

                            Recipient : Hutchmed

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            HUTCHMED Initiates Phase II/III Trial of Surufatinib & Camrelizumab for Pancreatic Cancer

                            Details : Hutchmed will initiate a clinical advancement of their lead product Sulanda (surufatinib) in combination with camrelizumab for the treatment of naïve pancreatic ductal adenocarcinoma.

                            Product Name : Sulanda

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            May 15, 2024

                            Lead Product(s) : Surufatinib,Camrelizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II/ Phase III

                            Recipient : Hutchmed

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            HengRui

                            U.S.A arrow
                            PREP
                            Not Confirmed

                            HengRui

                            U.S.A arrow
                            PREP
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fruquintinib,Sintilimab

                            Therapeutic Area : Oncology

                            Study Phase : Phase II/ Phase III

                            Recipient : Hutchmed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            HUTCHMED Initiates Phase II/III Trial of Surufatinib & Camrelizumab for Pancreatic Cancer

                            Details : Fruzaqla (fruquintinib) is a selective oral VEGFR inhibitor, playing a pivotal role in blocking tumor angiogenesis. It is being investigated in combination with sintilimab for endometrial cancer.

                            Product Name : Elunate

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            May 13, 2024

                            Lead Product(s) : Fruquintinib,Sintilimab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II/ Phase III

                            Recipient : Hutchmed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth